Poster-Disease-modifying Therapy
October 25, 2021
Real World Experience with Systemic Injection Reactions to Ofatumumab
Background: Ofatumumab is a subcutaneously administered B cell depleting agent approved by the FDA for use in patients with relapsing forms...
October 25, 2021
Cogeval in the Real World: Feasibility, Implementation, and Practical Implications
Background: Cognitive dysfunction in multiple sclerosis (MS) patients is common, and routine/efficient screening for cognitive dysfunction...